Corticosteroid 11-beta-dehydrogenase isozyme 2: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}}))
 
m ("progentitor" typo fix.)
 
Line 1: Line 1:
  <!-- The PBB_Controls template provides controls for Protein Box Bot, please see Template:PBB_Controls for details. -->
{{Infobox_gene}}
{{PBB_Controls
'''Corticosteroid 11-β-dehydrogenase isozyme 2''' also known as '''11-β-hydroxysteroid dehydrogenase 2''' is an [[enzyme]] that in humans is encoded by the ''HSD11B2'' [[gene]].<ref name="pmid7859916">{{cite journal | vauthors = Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS | title = Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme | journal = Mol. Cell. Endocrinol. | volume = 105 | issue = 2 | pages = R11–7 |date=November 1994 | pmid = 7859916 | doi = 10.1016/0303-7207(94)90176-7| url = }}</ref><ref name="pmid8611140">{{cite journal | vauthors = Brown RW, Chapman KE, Kotelevtsev Y, Yau JL, Lindsay RS, Brett L, Leckie C, Murad P, Lyons V, Mullins JJ, Edwards CR, Seckl JR | title = Cloning and production of antisera to human placental 11 beta-hydroxysteroid dehydrogenase type 2 | journal = Biochem. J. | volume = 313 | issue = Pt 3| pages = 1007–17 |date=February 1996 | pmid = 8611140 | pmc = 1216963 | doi = 10.1042/bj3131007| url =  }}</ref><ref name="entrez">{{cite web | title = Entrez Gene: HSD11B2 hydroxysteroid (11-beta) dehydrogenase 2| url = https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=3291| accessdate = }}</ref>
| update_page = yes
 
| require_manual_inspection = no
== Function ==
| update_protein_box = yes
 
| update_summary = yes
Corticosteroid 11-β-dehydrogenase isozyme 2 is an NAD<sup>+</sup>-dependent enzyme expressed in [[aldosterone]]-selective epithelial tissues such as the kidney, colon, salivary and sweat glands. HSD211B2 expression is also found in the [[brainstem]] in a small, aldosterone-sensitive subset of neurons located in the [[nucleus of the solitary tract]] referred to as [[HSD2 neurons]].<ref>{{Cite journal | first = Joel C. | last = Geerling |author2=Arthur D. Loewy |date=September 2009 | title = Aldosterone in the brain | journal = American Journal of Physiology. Renal Physiology | volume = 297 | pages = F559–76 | pmid = 19261742 | issue = 3 | doi = 10.1152/ajprenal.90399.2008 | pmc = 2739715 }}</ref>
| update_citations = yes
 
}}
In these tissues, HSD11B2 oxidizes the glucocorticoid [[cortisol]] to the inactive metabolite [[cortisone]], thus preventing illicit activation of the [[mineralocorticoid receptor]]. This protective mechanism is necessary because cortisol circulates at 100-1000-fold higher concentrations than aldosterone, and binds with equal affinity to the mineralocorticoid receptor, thereby out-competing aldosterone in cells that do not produce HSD11B2.


<!-- The GNF_Protein_box is automatically maintained by Protein Box Bot.  See Template:PBB_Controls to Stop updates. -->
This glucocorticoid-inactivating enzyme is also expressed in tissues that do not express the mineralocorticoid receptor, such as the placenta and testis, as well as parts of the developing brain, including the rhombencephalic progenitor cells that proliferate into cerebellar [[granule cells]]. In these tissues, HSD11B2 protects cells from the growth-inhibiting and/or pro-apoptotic effects of cortisol, particularly during embryonic development.
{{GNF_Protein_box
| image = 
| image_source = 
| PDB =
| Name = Hydroxysteroid (11-beta) dehydrogenase 2
| HGNCid = 5209
| Symbol = HSD11B2
| AltSymbols =; AME; AME1; HSD11K; HSD2
| OMIM = 218030
| ECnumber = 
| Homologene = 20088
| MGIid = 104720
| GeneAtlas_image1 = PBB_GE_HSD11B2_204130_at_tn.png
| Function = {{GNF_GO|id=GO:0016491 |text = oxidoreductase activity}}
| Component = {{GNF_GO|id=GO:0005783 |text = endoplasmic reticulum}} {{GNF_GO|id=GO:0005792 |text = microsome}}
| Process = {{GNF_GO|id=GO:0006704 |text = glucocorticoid biosynthetic process}} {{GNF_GO|id=GO:0007267 |text = cell-cell signaling}} {{GNF_GO|id=GO:0008152 |text = metabolic process}}
| Orthologs = {{GNF_Ortholog_box
    | Hs_EntrezGene = 3291
    | Hs_Ensembl = ENSG00000176387
    | Hs_RefseqProtein = NP_000187
    | Hs_RefseqmRNA = NM_000196
    | Hs_GenLoc_db = 
    | Hs_GenLoc_chr = 16
    | Hs_GenLoc_start = 66022518
    | Hs_GenLoc_end = 66028953
    | Hs_Uniprot = P80365
    | Mm_EntrezGene = 15484
    | Mm_Ensembl = ENSMUSG00000031891
    | Mm_RefseqmRNA = NM_008289
    | Mm_RefseqProtein = NP_032315
    | Mm_GenLoc_db = 
    | Mm_GenLoc_chr = 8
    | Mm_GenLoc_start = 108407884
    | Mm_GenLoc_end = 108413115
    | Mm_Uniprot = Q3U2R0
  }}
}}
'''Hydroxysteroid (11-beta) dehydrogenase 2''', also known as '''HSD11B2''', is
a human [[gene]].<ref name="entrez">{{cite web | title = Entrez Gene: HSD11B2 hydroxysteroid (11-beta) dehydrogenase 2| url = http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=3291| accessdate = }}</ref> It encodes an NAD+-dependent enzyme expressed in [[aldosterone]]-selective tissues.


In these tissues, HSD11B2 oxidizes [[cortisol]] to [[cortisone]] and prevents illicit activation of the [[mineralocorticoid receptor]].
== Clinical significance ==


Inhibition of this enzyme results in a condition known as [[pseudohyperaldosteronism]]
Inhibition of this enzyme, for example by a compound in liquorice, results in a condition known as [[pseudohyperaldosteronism]]. A genetically inherited deficiency of HSD11B2 is the underlying cause of the [[syndrome of apparent mineralocorticoid excess]].


==References==
==References==
{{reflist|2}}
{{reflist}}
 
==Further reading==
==Further reading==
{{refbegin | 2}}
{{refbegin | 2}}
{{PBB_Further_reading  
{{PBB_Further_reading  
| citations =  
| citations =  
*{{cite journal  | author=White PC, Mune T, Agarwal AK |title=11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. |journal=Endocr. Rev. |volume=18 |issue= 1 |pages= 135-56 |year= 1997 |pmid= 9034789 |doi=  }}
*{{cite journal  | vauthors=White PC, Mune T, Agarwal AK |title=11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess |journal=Endocr. Rev. |volume=18 |issue= 1 |pages= 135–56 |year= 1997 |pmid= 9034789 |doi=10.1210/er.18.1.135 }}
*{{cite journal  | author=Wilson RC, Dave-Sharma S, Wei JQ, ''et al.'' |title=A genetic defect resulting in mild low-renin hypertension. |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=95 |issue= 17 |pages= 10200-5 |year= 1998 |pmid= 9707624 |doi=  }}
*{{cite journal  | author=Wilson RC |title=A genetic defect resulting in mild low-renin hypertension |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=95 |issue= 17 |pages= 10200–5 |year= 1998 |pmid= 9707624 |doi=10.1073/pnas.95.17.10200 | pmc=21485 |name-list-format=vanc| author2=Dave-Sharma S  | author3=Wei JQ  | display-authors=3  | last4=Obeyesekere  | first4=VR  | last5=Li  | first5=K  | last6=Ferrari  | first6=P  | last7=Krozowski  | first7=ZS  | last8=Shackleton  | first8=CH  | last9=Bradlow  | first9=L }}
*{{cite journal | author=Quinkler M, Stewart PM |title=Hypertension and the cortisol-cortisone shuttle. |journal=J. Clin. Endocrinol. Metab. |volume=88 |issue= 6 |pages= 2384-92 |year= 2003 |pmid= 12788832 |doi=  }}
*{{cite journal  | vauthors=Quinkler M, Stewart PM |title=Hypertension and the cortisol-cortisone shuttle |journal=J. Clin. Endocrinol. Metab. |volume=88 |issue= 6 |pages= 2384–92 |year= 2003 |pmid= 12788832 |doi=10.1210/jc.2003-030138  }}
*{{cite journal  | author=Tomlinson JW, Walker EA, Bujalska IJ, ''et al.'' |title=11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. |journal=Endocr. Rev. |volume=25 |issue= 5 |pages= 831-66 |year= 2005 |pmid= 15466942 |doi= 10.1210/er.2003-0031 }}
*{{cite journal  | author=Tomlinson JW |title=11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response |journal=Endocr. Rev. |volume=25 |issue= 5 |pages= 831–66 |year= 2005 |pmid= 15466942 |doi= 10.1210/er.2003-0031 |name-list-format=vanc| author2=Walker EA  | author3=Bujalska IJ  | display-authors=3  | last4=Draper  | first4=N  | last5=Lavery  | first5=GG  | last6=Cooper  | first6=MS  | last7=Hewison  | first7=M  | last8=Stewart | first8=PM }}
*{{cite journal  | author=Persu A |title=11beta-Hydroxysteroid deshydrogenase: a multi-faceted enzyme. |journal=J. Hypertens. |volume=23 |issue= 1 |pages= 29-31 |year= 2005 |pmid= 15643119 |doi= }}
*{{cite journal  | author=Persu A |title=11beta-Hydroxysteroid deshydrogenase: a multi-faceted enzyme |journal=J. Hypertens. |volume=23 |issue= 1 |pages= 29–31 |year= 2005 |pmid= 15643119 |doi=  10.1097/00004872-200501000-00007}}
*{{cite journal | author=Funder JW, Pearce PT, Smith R, Smith AI |title=Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. |journal=Science |volume=242 |issue= 4878 |pages= 583-5 |year= 1988 |pmid= 2845584 |doi=  }}
*{{cite journal  | vauthors=Funder JW, Pearce PT, Smith R, Smith AI |title=Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated |journal=Science |volume=242 |issue= 4878 |pages= 583–5 |year= 1988 |pmid= 2845584 |doi=10.1126/science.2845584 }}
*{{cite journal  | author=Stewart PM, Wallace AM, Valentino R, ''et al.'' |title=Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. |journal=Lancet |volume=2 |issue= 8563 |pages= 821-4 |year= 1987 |pmid= 2889032 |doi=  }}
*{{cite journal  | author=Stewart PM |title=Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age |journal=Lancet |volume=2 |issue= 8563 |pages= 821–4 |year= 1987 |pmid= 2889032 |doi=10.1016/S0140-6736(87)91014-2 |name-list-format=vanc| author2=Wallace AM  | author3=Valentino R  | display-authors=3  | last4=Burt  | first4=Daniel  | last5=Shackleton  | first5=Cedrich.L.  | last6=Edwards  | first6=Christopherr.W. }}
*{{cite journal  | author=Wilson RC, Harbison MD, Krozowski ZS, ''et al.'' |title=Several homozygous mutations in the gene for 11 beta-hydroxysteroid dehydrogenase type 2 in patients with apparent mineralocorticoid excess. |journal=J. Clin. Endocrinol. Metab. |volume=80 |issue= 11 |pages= 3145-50 |year= 1995 |pmid= 7593417 |doi=  }}
*{{cite journal  | author=Wilson RC |title=Several homozygous mutations in the gene for 11 beta-hydroxysteroid dehydrogenase type 2 in patients with apparent mineralocorticoid excess |journal=J. Clin. Endocrinol. Metab. |volume=80 |issue= 11 |pages= 3145–50 |year= 1995 |pmid= 7593417 |doi=10.1210/jc.80.11.3145  |name-list-format=vanc| author2=Harbison MD | author3=Krozowski ZS | display-authors=3  | last4=Funder  | first4=JW  | last5=Shackleton  | first5=CH  | last6=Hanauske-Abel  | first6=HM  | last7=Wei  | first7=JQ  | last8=Hertecant  | first8=J  | last9=Moran  | first9=A }}
*{{cite journal  | author=Wilson RC, Krozowski ZS, Li K, ''et al.'' |title=A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. |journal=J. Clin. Endocrinol. Metab. |volume=80 |issue= 7 |pages= 2263-6 |year= 1995 |pmid= 7608290 |doi= }}
*{{cite journal  | author=Wilson RC |title=A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess |journal=J. Clin. Endocrinol. Metab. |volume=80 |issue= 7 |pages= 2263–6 |year= 1995 |pmid= 7608290 |doi=10.1210/jc.80.7.2263 |name-list-format=vanc| author2=Krozowski ZS  | author3=Li K  | display-authors=3  | last4=Obeyesekere  | first4=VR  | last5=Razzaghy-Azar  | first5=M  | last6=Harbison  | first6=MD  | last7=Wei  | first7=JQ  | last8=Shackleton  | first8=CH  | last9=Funder  | first9=JW }}
*{{cite journal | author=Krozowski Z, Baker E, Obeyesekere V, Callen DF |title=Localization of the gene for human 11 beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) to chromosome band 16q22. |journal=Cytogenet. Cell Genet. |volume=71 |issue= 2 |pages= 124-5 |year= 1995 |pmid= 7656579 |doi=  }}
*{{cite journal  | vauthors=Krozowski Z, Baker E, Obeyesekere V, Callen DF |title=Localization of the gene for human 11 beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) to chromosome band 16q22 |journal=Cytogenet. Cell Genet. |volume=71 |issue= 2 |pages= 124–5 |year= 1995 |pmid= 7656579 |doi=10.1159/000134089 }}
*{{cite journal  | author=Mune T, Rogerson FM, Nikkilä H, ''et al.'' |title=Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase. |journal=Nat. Genet. |volume=10 |issue= 4 |pages= 394-9 |year= 1995 |pmid= 7670488 |doi= 10.1038/ng0895-394 }}
*{{cite journal  | author=Mune T |title=Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase |journal=Nat. Genet. |volume=10 |issue= 4 |pages= 394–9 |year= 1995 |pmid= 7670488 |doi= 10.1038/ng0895-394 |name-list-format=vanc| author2=Rogerson FM | author3=Nikkilä H  | display-authors=3  | last4=Agarwal  | first4=Anil K. | last5=White  | first5=Perrin C. }}
*{{cite journal | author=Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS |title=Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme. |journal=Mol. Cell. Endocrinol. |volume=105 |issue= 2 |pages= R11-7 |year= 1995 |pmid= 7859916 |doi=  }}
*{{cite journal  | vauthors=Agarwal AK, Rogerson FM, Mune T, White PC |title=Gene structure and chromosomal localization of the human HSD11K gene encoding the kidney (type 2) isozyme of 11 beta-hydroxysteroid dehydrogenase |journal=Genomics |volume=29 |issue= 1 |pages= 195–9 |year= 1996 |pmid= 8530071 |doi= 10.1006/geno.1995.1231 }}
*{{cite journal  | author=Agarwal AK, Rogerson FM, Mune T, White PC |title=Gene structure and chromosomal localization of the human HSD11K gene encoding the kidney (type 2) isozyme of 11 beta-hydroxysteroid dehydrogenase. |journal=Genomics |volume=29 |issue= 1 |pages= 195-9 |year= 1996 |pmid= 8530071 |doi= 10.1006/geno.1995.1231 }}
*{{cite journal  | author=Krozowski Z |title=The human 11 beta-hydroxysteroid dehydrogenase type II enzyme: comparisons with other species and localization to the distal nephron |journal=J. Steroid Biochem. Mol. Biol. |volume=55 |issue= 5–6 |pages= 457–64 |year= 1996 |pmid= 8547170 |doi=10.1016/0960-0760(95)00194-8 |name-list-format=vanc| author2=Albiston AL  | author3=Obeyesekere VR  | display-authors=3  | last4=Andrews  | first4=R.K.  | last5=Smith  | first5=R.E. }}
*{{cite journal | author=Krozowski Z, Albiston AL, Obeyesekere VR, ''et al.'' |title=The human 11 beta-hydroxysteroid dehydrogenase type II enzyme: comparisons with other species and localization to the distal nephron. |journal=J. Steroid Biochem. Mol. Biol. |volume=55 |issue= 5-6 |pages= 457-64 |year= 1996 |pmid= 8547170 |doi=  }}
*{{cite journal  | author=Brown RW |title=Purification of 11 beta-hydroxysteroid dehydrogenase type 2 from human placenta utilizing a novel affinity labelling technique |journal=Biochem. J. |volume=313 |issue= Pt 3|pages= 997–1005 |year= 1996 |pmid= 8611186 |doi=  10.1042/bj3130997| pmc=1217009  |name-list-format=vanc| author2=Chapman KE  | author3=Murad P  | display-authors=3  | last4=Edwards  | first4=CR  | last5=Seckl  | first5=JR  }}
*{{cite journal  | author=Brown RW, Chapman KE, Kotelevtsev Y, ''et al.'' |title=Cloning and production of antisera to human placental 11 beta-hydroxysteroid dehydrogenase type 2. |journal=Biochem. J. |volume=313 ( Pt 3) |issue= |pages= 1007-17 |year= 1996 |pmid= 8611140 |doi=  }}
*{{cite journal  | author=Kitanaka S |title=A new compound heterozygous mutation in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess |journal=J. Clin. Endocrinol. Metab. |volume=82 |issue= 12 |pages= 4054–8 |year= 1998 |pmid= 9398712 |doi=10.1210/jc.82.12.4054  |name-list-format=vanc| author2=Katsumata N  | author3=Tanae A  | display-authors=3  | last4=Hibi  | first4=I  | last5=Takeyama  | first5=K  | last6=Fuse  | first6=H  | last7=Kato  | first7=S  | last8=Tanaka  | first8=T  }}
*{{cite journal  | author=Brown RW, Chapman KE, Murad P, ''et al.'' |title=Purification of 11 beta-hydroxysteroid dehydrogenase type 2 from human placenta utilizing a novel affinity labelling technique. |journal=Biochem. J. |volume=313 ( Pt 3) |issue= |pages= 997-1005 |year= 1996 |pmid= 8611186 |doi=  }}
*{{cite journal  | author=Dave-Sharma S |title=Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess |journal=J. Clin. Endocrinol. Metab. |volume=83 |issue= 7 |pages= 2244–54 |year= 1998 |pmid= 9661590 |doi=10.1210/jc.83.7.2244  |name-list-format=vanc| author2=Wilson RC  | author3=Harbison MD  | display-authors=3  | last4=Newfield  | first4=R  | last5=Azar  | first5=MR  | last6=Krozowski  | first6=ZS  | last7=Funder  | first7=JW  | last8=Shackleton  | first8=CH  | last9=Bradlow  | first9=HL  }}
*{{cite journal | author=Kitanaka S, Katsumata N, Tanae A, ''et al.'' |title=A new compound heterozygous mutation in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess. |journal=J. Clin. Endocrinol. Metab. |volume=82 |issue= 12 |pages= 4054-8 |year= 1998 |pmid= 9398712 |doi= }}
*{{cite journal  | author=Li A |title=Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess |journal=Am. J. Hum. Genet. |volume=63 |issue= 2 |pages= 370–9 |year= 1998 |pmid= 9683587 |doi=10.1086/301955  | pmc=1377297  |name-list-format=vanc| author2=Tedde R  | author3=Krozowski ZS  | display-authors=3  | last4=Pala  | first4=A.  | last5=Li  | first5=K.X.Z.  | last6=Shackleton  | first6=C.H.L.  | last7=Mantero  | first7=F.  | last8=Palermo  | first8=M.  | last9=Stewart  | first9=P.M. }}
*{{cite journal  | author=Dave-Sharma S, Wilson RC, Harbison MD, ''et al.'' |title=Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. |journal=J. Clin. Endocrinol. Metab. |volume=83 |issue= 7 |pages= 2244-54 |year= 1998 |pmid= 9661590 |doi= }}
*{{cite journal | author=Li A, Tedde R, Krozowski ZS, ''et al.'' |title=Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess. |journal=Am. J. Hum. Genet. |volume=63 |issue= 2 |pages= 370-9 |year= 1998 |pmid= 9683587 |doi=  }}
}}
}}
{{refend}}
{{refend}}


{{oxidoreductase-stub}}
{{Steroid metabolism enymes}}
{{Alcohol oxidoreductases}}
{{Alcohol oxidoreductases}}
[[Category:Enzymes]]
{{Enzymes}}
{{Portal bar|Molecular and Cellular Biology|border=no}}
 
<!-- The PBB_Controls template provides controls for Protein Box Bot, please see Template:PBB_Controls for details. -->
{{PBB_Controls
| update_page = yes
| require_manual_inspection = no
| update_protein_box = yes
| update_summary = no
| update_citations = no
}}
 
[[Category:EC 1.1.1]]

Latest revision as of 06:09, 8 September 2017

VALUE_ERROR (nil)
Identifiers
Aliases
External IDsGeneCards: [1]
Orthologs
SpeciesHumanMouse
Entrez

n/a

n/a

Ensembl

n/a

n/a

UniProt

n/a

n/a

RefSeq (mRNA)

n/a

n/a

RefSeq (protein)

n/a

n/a

Location (UCSC)n/an/a
PubMed searchn/an/a
Wikidata
View/Edit Human

Corticosteroid 11-β-dehydrogenase isozyme 2 also known as 11-β-hydroxysteroid dehydrogenase 2 is an enzyme that in humans is encoded by the HSD11B2 gene.[1][2][3]

Function

Corticosteroid 11-β-dehydrogenase isozyme 2 is an NAD+-dependent enzyme expressed in aldosterone-selective epithelial tissues such as the kidney, colon, salivary and sweat glands. HSD211B2 expression is also found in the brainstem in a small, aldosterone-sensitive subset of neurons located in the nucleus of the solitary tract referred to as HSD2 neurons.[4]

In these tissues, HSD11B2 oxidizes the glucocorticoid cortisol to the inactive metabolite cortisone, thus preventing illicit activation of the mineralocorticoid receptor. This protective mechanism is necessary because cortisol circulates at 100-1000-fold higher concentrations than aldosterone, and binds with equal affinity to the mineralocorticoid receptor, thereby out-competing aldosterone in cells that do not produce HSD11B2.

This glucocorticoid-inactivating enzyme is also expressed in tissues that do not express the mineralocorticoid receptor, such as the placenta and testis, as well as parts of the developing brain, including the rhombencephalic progenitor cells that proliferate into cerebellar granule cells. In these tissues, HSD11B2 protects cells from the growth-inhibiting and/or pro-apoptotic effects of cortisol, particularly during embryonic development.

Clinical significance

Inhibition of this enzyme, for example by a compound in liquorice, results in a condition known as pseudohyperaldosteronism. A genetically inherited deficiency of HSD11B2 is the underlying cause of the syndrome of apparent mineralocorticoid excess.

References

  1. ↑ Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS (November 1994). "Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme". Mol. Cell. Endocrinol. 105 (2): R11–7. doi:10.1016/0303-7207(94)90176-7. PMID 7859916.
  2. ↑ Brown RW, Chapman KE, Kotelevtsev Y, Yau JL, Lindsay RS, Brett L, Leckie C, Murad P, Lyons V, Mullins JJ, Edwards CR, Seckl JR (February 1996). "Cloning and production of antisera to human placental 11 beta-hydroxysteroid dehydrogenase type 2". Biochem. J. 313 (Pt 3): 1007–17. doi:10.1042/bj3131007. PMC 1216963. PMID 8611140.
  3. ↑ "Entrez Gene: HSD11B2 hydroxysteroid (11-beta) dehydrogenase 2".
  4. ↑ Geerling, Joel C.; Arthur D. Loewy (September 2009). "Aldosterone in the brain". American Journal of Physiology. Renal Physiology. 297 (3): F559–76. doi:10.1152/ajprenal.90399.2008. PMC 2739715. PMID 19261742.

Further reading

Retrieved from "https://www.wikidoc.org/index.php?title=Corticosteroid_11-beta-dehydrogenase_isozyme_2&oldid=1417195"